A
ORKA

AlphaQuest’s Oruka Therapeutics ORKA Stock Holding History

AlphaQuest’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,901
Closed -$452K – 2207
2025
Q4 		$452K Buy
14,901
+4,140
+38% +$115K 0.03% 903
2025
Q3 		$207K Sell
10,761
-5,303
-33% -$78.6K 0.01% 1388
2025
Q2 		$180K Sell
16,064
-271
-2% -$2.82K 0.02% 1192
2025
Q1 		$168K Buy
+16,335
New +$204K 0.02% 1068

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AlphaQuest's ORKA Position: Q1 2026 in Review

AlphaQuest sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 14,901 shares — an estimated $452K sold.

AlphaQuest first reported a position in ORKA in Q1 2025 and held it in 4 quarters. The position peaked at $452K in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • AlphaQuest reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 14,901 Oruka Therapeutics shares in Q1 2026, an estimated $452K.
  • AlphaQuest first reported a position in Oruka Therapeutics in Q1 2025 and held it in 4 quarters.
  • AlphaQuest's Oruka Therapeutics position peaked at $452K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.